Skip Nav Destination
Issues
15 February 2017
-
Cover Image
Cover Image
The cover shows a section of a patient-derived xenograft tumor generated from an adenoid cystic carcinoma. Immunohistochemical staining shows strong expression of the cancer stem cell marker aldehyde dehydrogenase (ALDH) in close proximity to blood vessels and nerves. For details, see the article by Nör and colleagues on page 1036 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
Review
Perspectives
Cancer Therapy: Clinical
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Keith W. Pratz; Michelle A. Rudek; Ivana Gojo; Mark R. Litzow; Michael A. McDevitt; Jiuping Ji; Larry M. Karnitz; James G. Herman; Robert J. Kinders; B. Douglas Smith; Steven D. Gore; Hetty E. Carraway; Margaret M. Showel; Douglas E. Gladstone; Mark J. Levis; Hua-Ling Tsai; Gary Rosner; Alice Chen; Scott H. Kaufmann; Judith E. Karp
First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas
Sylvie Bonvalot; Cécile Le Pechoux; Thierry De Baere; Guy Kantor; Xavier Buy; Eberhard Stoeckle; Philippe Terrier; Paul Sargos; Jean Michel Coindre; Nathalie Lassau; Rafik Ait Sarkouh; Mikaela Dimitriu; Elsa Borghi; Laurent Levy; Eric Deutsch; Jean-Charles Soria
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
Charlotte S. Lo; Sanaz Sanii; David R. Kroeger; Katy Milne; Aline Talhouk; Derek S. Chiu; Kurosh Rahimi; Patricia A. Shaw; Blaise A. Clarke; Brad H. Nelson
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer
Rana R. McKay; Lillian Werner; Elahe A. Mostaghel; Rosina Lis; Olga Voznesensky; Zhenwei Zhang; Brett T. Marck; Alvin M. Matsumoto; Liran Domachevsky; Katherine A. Zukotynski; Manoj Bhasin; Glenn J. Bubley; Bruce Montgomery; Philip W. Kantoff; Steven P. Balk; Mary-Ellen Taplin
Personalized Medicine and Imaging
Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma
Priya Chudasama; Marcus Renner; Melanie Straub; Sadaf S. Mughal; Barbara Hutter; Zeynep Kosaloglu; Ron Schweßinger; Matthias Scheffler; Ingo Alldinger; Simon Schimmack; Thorsten Persigehl; Carsten Kobe; Dirk Jäger; Christof von Kalle; Peter Schirmacher; Marie-Kristin Beckhaus; Stephan Wolf; Christoph Heining; Stefan Gröschel; Jürgen Wolf; Benedikt Brors; Wilko Weichert; Hanno Glimm; Claudia Scholl; Gunhild Mechtersheimer; Katja Specht; Stefan Fröhling
Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
Ganesh S. Palapattu; Simpa S. Salami; Andi K. Cani; Daniel H. Hovelson; Lorena Lazo de la Vega; Kelly R. Vandenberg; Jarred V. Bratley; Chia-Jen Liu; Lakshmi P. Kunju; Jeffery S. Montgomery; Todd M. Morgan; Shyam Natarajan; Jiaoti Huang; Scott A. Tomlins; Leonard S. Marks
Cancer Therapy: Preclinical
ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
Jieyi Wang; Mark G. Anderson; Anatol Oleksijew; Kedar S. Vaidya; Erwin R. Boghaert; Lora Tucker; Qian Zhang; Edward K. Han; Joann P. Palma; Louie Naumovski; Edward B. Reilly
Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors
Wael Jdey; Sylvain Thierry; Christophe Russo; Flavien Devun; Muthana Al Abo; Patricia Noguiez-Hellin; Jian-Sheng Sun; Emmanuel Barillot; Andrei Zinovyev; Inna Kuperstein; Yves Pommier; Marie Dutreix
Author Choice
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Yana Pikman; Gabriela Alexe; Giovanni Roti; Amy Saur Conway; Andrew Furman; Emily S. Lee; Andrew E. Place; Sunkyu Kim; Chitra Saran; Rebecca Modiste; David M. Weinstock; Marian Harris; Andrew L. Kung; Lewis B. Silverman; Kimberly Stegmaier
Author Choice
TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
Penka S. Petrova; Natasja Nielsen Viller; Mark Wong; Xinli Pang; Gloria H.Y. Lin; Karen Dodge; Vien Chai; Hui Chen; Vivian Lee; Violetta House; Noel T. Vigo; Debbie Jin; Tapfuma Mutukura; Marilyse Charbonneau; Tran Truong; Stephane Viau; Lisa D. Johnson; Emma Linderoth; Eric L. Sievers; Saman Maleki Vareki; Rene Figueredo; Macarena Pampillo; James Koropatnick; Suzanne Trudel; Nathan Mbong; Liqing Jin; Jean C.Y. Wang; Robert A. Uger
Biology of Human Tumors
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds